Diagnosis and Treatment of Castleman Disease: The Role of the Oncology Nurse
Faculty
David C. Fajgenbaum, MD, MBA, MSc
Assistant Professor of Medicine
Division of Translational Medicine and Human Genetics
University of Pennsylvania
Associate Director, Patient Impact
Penn Orphan Disease Center
Founding Director
Center for Cytokine Storm Treatment & Laboratory
Co-Founder and Executive Director
Castleman Disease Collaborative Network
Philadelphia, PA
Frits van Rhee, MD, PhD
Professor of Medicine
Clinical Director
UAMS Myeloma Center
University of Arkansas for Medical Sciences
Little Rock, AR
Steering Committee
Colleen Erb, CRNP
Nurse Practitioner
Perelman Center for Advanced Medicine
Philadelphia, PA
This activity is jointly provided by Global Education Group and Paradigm Medical Communications, LLC.
In collaboration with the Castleman Disease Collaborative Network. 
Disclosure of Commercial Support
This activity is supported by an educational grant from EUSA Pharma.
Target Audience
This activity has been designed to address the educational needs of oncology nurses, including advanced practice nurses (APNs) and registered nurses (RNs). It will also benefit other clinicians who manage patients with Castleman disease.
Learning Objectives
After completing this activity, the participant should be better able to:
- Outline the signs and symptoms of Castleman disease as they relate to early diagnosis
- Describe FDA-approved and guideline-recommended therapies for Castleman disease
Agenda
- Introduction to Castleman Disease
- Diagnosis of Castleman Disease
- Treatment of Castleman Disease
- The Patient's Journey
- Case Studies
- Conclusions
- Q&A
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Paradigm Medical Communications, LLC. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.25 contact hours (which includes 0.1 hour(s) of pharmacology).
Global Contact Information
For information about the approval of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
How to Receive Your CE Credit
To receive a CE certificate of participation, you must:
- View the live virtual presentation in its entirety
- Click on the Claim Credit tab within the Array Virtual Platform to complete your evaluation and posttest
- If you do not click on the Claim Credit tab within the Array Virtual Platform, you will receive an email with instructions to log in and complete and submit your online evaluation and posttest following the meeting
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
There is no fee required for participation in this activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter | Reported Financial Relationship |
|---|---|
David C. Fajgenbaum, MD, MBA, MSc | Grant/Research Support: EUSA Pharma; |
Frits van Rhee, MD, PhD | Consulting Fees: Adaptive Biotechnologies; EUSA Pharma; Karyopharm; Secura Bio; |
Colleen Erb, CRNP | No financial relationships to disclose |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
| Name of Planner or Manager | Reported Financial Relationship |
| Ashley Marostica, RN, MSN | No financial relationships to disclose |
| Kristin Delisi, NP | No financial relationships to disclose |
| Andrea Funk | No financial relationships to disclose |
| Liddy Knight | No financial relationships to disclose |
| Ashley Cann | No financial relationships to disclose |
| Andrea Primeau | No financial relationships to disclose |
| Alfred Saint Jacques | No financial relationships to disclose |
| Kimberly Joab | No financial relationships to disclose |
Resolution of Conflict of Interest
Global and Paradigm have implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity has been independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Paradigm do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.